AP Biosciences Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	1,641	278.61	1,048
Short-Term Investments	100	461.41	30.71
Cash & Short-Term Investments	1,741	740.02	1,079
Cash Growth	79.21%	-31.40%	-
Other Receivables	26.4	24.6	14.48
Receivables	26.4	24.6	14.48
Prepaid Expenses	2.67	1.03	0.85
Total Current Assets	1,770	765.64	1,094
Property, Plant & Equipment	112.43	116.41	3.02
Other Intangible Assets	3.83	4.23	5.34
Other Long-Term Assets	3.29	4.48	0.78
Total Assets	1,890	890.76	1,103
Accrued Expenses	17.03	16.72	2.48
Current Portion of Leases	11.65	11.65	-
Other Current Liabilities	4.11	2.51	2.04
Total Current Liabilities	32.79	30.88	4.52
Long-Term Leases	64.87	70.43	-
Other Long-Term Liabilities	5.4	5.35	-
Total Liabilities	103.06	106.65	4.52
Common Stock	848.71	647.48	647.48
Additional Paid-In Capital	1,164	475.92	739.72
Retained Earnings	-226.27	-339.3	-288.54
Shareholders' Equity	1,787	784.11	1,099
Total Liabilities & Equity	1,890	890.76	1,103
Total Debt	76.52	82.08	-
Net Cash (Debt)	1,665	657.94	1,079
Net Cash Growth	87.87%	-39.01%	-
Net Cash Per Share	25.54	10.16	20.49
Filing Date Shares Outstanding	84.87	64.75	56.55
Total Common Shares Outstanding	84.87	64.75	56.55
Working Capital	1,737	734.77	1,090
Book Value Per Share	21.05	12.11	19.43
Tangible Book Value	1,783	779.88	1,093
Tangible Book Value Per Share	21.01	12.04	19.33
Machinery	39.16	36.93	31.34
Leasehold Improvements	-	28.2	1

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.